Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2018
Reporting Period: Quarter ended March 31, 2018
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the announcement of financial results for the quarter ended March 31, 2018. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this filing. The filing states that the full details are provided in the press release furnished as Exhibit 99.1.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company announced its financial results on May 8, 2018. The full text of the press release is incorporated by reference.
Legal Disclaimer: The information in this Current Report, including the press release, is furnished to comply with Item 2.02 of Form 8-K. It shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section, except as expressly set forth by specific reference in another filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 8, 2018) for specific revenue, net loss, and cash position figures.
- Verify the Company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.
- Confirm the exact date of the financial results announcement (May 8, 2018) against market data.
- Note that this 8-K text itself does not contain the financial tables or detailed operational metrics.